AtaiBeckley To Host Virtual Investor Day on March 6, 2026
AtaiBeckley (NASDAQ: ATAI) will host a Virtual Investor Day on Friday, March 6, 2026, from 9:00 a.m. to 12:00 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
AtaiBeckley (NASDAQ: ATAI) will host a Virtual Investor Day on Friday, March 6, 2026, from 9:00 a.m. to 12:00 p.m. ET. The event will include presentations and live Q&A with the company’s executive leadership and external key opinion leaders.
Investors, analysts, and media may register for the live webcast; a replay will be posted afterward on the company’s investor website under Events.
Details
News Market Reaction – ATAI
On Feb 20, the day this news came out, ATAI closed 1.57% above the previous close.
Data tracked by StockTitan Argus for the Feb 20 session.
Key Figures
- Share price
- $3.82
- Pre-news current price for ATAI
- Daily change
- -3.29%
- Price change over the prior 24 hours
- 52-week high
- $6.75
- Upper end of 52-week trading range
- 52-week low
- $1.15
- Lower end of 52-week trading range
- Vs 52-week high
- -43.41%
- Distance from 52-week high before this news
- Vs 52-week low
- 232.17%
- Gain from 52-week low before this news
- Market cap
- $1,434,697,678
- Equity value prior to the Investor Day announcement
- Investor Day time
- 9:00 a.m.–12:00 p.m. ET
- Scheduled window for March 6, 2026 virtual event
Historical Context
-
Named experienced CFO effective March 9, 2026 and highlighted BPL-003 progress.
-
Announced multiple March 2026 investor conference appearances and webcasts.
-
Reported positive Phase 2b BPL-003 data and supportive preclinical 5-MeO-DMT results.
-
Provided 2026 outlook with Phase 3 plans and multiple upcoming readouts.
-
Completed redomiciliation to Delaware with one-for-one share exchange and high approval.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that it will host a Virtual Investor Day on Friday, March 6, 2026, from 9:00 a.m. to 12:00 p.m. ET. The event will feature presentations and live Q&A sessions with members of the Company’s executive leadership team and several external key opinion leaders.
Investors, analysts, and members of the media are invited to register for the live webcast. A replay will be made available following the event on the investor section of the AtaiBeckley website, under Events.
Registration Link: https://app.webinar.net/7e5Jn1zYlXj
About AtaiBeckley Inc.
AtaiBeckley is a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments. AtaiBeckley’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder. BPL-003 is in Phase 3 planning, VLS-01 and EMP-01 are in Phase 2 clinical development. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. These programs aim to create breakthroughs in mental health through transformative interventional psychiatry therapies that can integrate seamlessly into healthcare systems.
For the latest updates and to learn more about the AtaiBeckley mission, visit www.ataibeckley.com or follow the Company on LinkedIn and on X.
Contact Information:
Investors:
Jason Awe, PhD
VP, Investor Relations
IR@ataibeckley.com
Media:
Charlotte Chorley
Associate Director, Communications
PR@ataibeckley.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.